PDF, 131.54 KB - Indian Journal of Pharmacy Practice
... The early attempts of enzyme replacement therapy treatment were for gaucher disease by β-glucosidase which was firstly purified from placenta in 1974. Physical therapy is an important component of management. Recently, the recombinant acid α-glucosidase purified from mice milk was internalized via t ...
... The early attempts of enzyme replacement therapy treatment were for gaucher disease by β-glucosidase which was firstly purified from placenta in 1974. Physical therapy is an important component of management. Recently, the recombinant acid α-glucosidase purified from mice milk was internalized via t ...
Aetiopathogenesis and Treatment of Vitiligo
... area of untreated vitiligo subjects can also not be passaged, i.e. they do not survive detachment by trypsinization, while melanocytes from normal humans survive many such detachments from culture dishes." The melanocytes from perilesional areas of untreated vitiligo patients do not grow at all in c ...
... area of untreated vitiligo subjects can also not be passaged, i.e. they do not survive detachment by trypsinization, while melanocytes from normal humans survive many such detachments from culture dishes." The melanocytes from perilesional areas of untreated vitiligo patients do not grow at all in c ...
Cancer Prone Disease Section Fanconi anaemia Atlas of Genetics and Cytogenetics
... bone marrow engraftment has been decided in a pancytopenic patient: if this patient has FA, bone marrow conditioning must be very mild, as FA cells are very clastogen sensitive. The recent discover of genes involved in the disease should improve diagnostic ...
... bone marrow engraftment has been decided in a pancytopenic patient: if this patient has FA, bone marrow conditioning must be very mild, as FA cells are very clastogen sensitive. The recent discover of genes involved in the disease should improve diagnostic ...
The postoperative bleeding rate and its risk factors in patients on
... factors yielded odds ratios of 1.04 for ESD duration, 14.83 for LDA + warfarin combination therapy, and 0.27 for PPI + mucosal protective agent combination therapy. Conclusions: The risk of postoperative hemorrhage following gastric ESD was higher in patients with antithrombotic therapy than in thos ...
... factors yielded odds ratios of 1.04 for ESD duration, 14.83 for LDA + warfarin combination therapy, and 0.27 for PPI + mucosal protective agent combination therapy. Conclusions: The risk of postoperative hemorrhage following gastric ESD was higher in patients with antithrombotic therapy than in thos ...
PPT - Glasnost
... `Yeast' has a gene count of 6000 `Thale cress' has a gene count of 26000 -----------------------------------------------------------`Fruit fly' has a gene count of 13000 `Human' has a gene count of 31000 `Nematode worm' has a gene count of 18000 `Thale cress' has a gene count of 26000 `Tuberculosis ...
... `Yeast' has a gene count of 6000 `Thale cress' has a gene count of 26000 -----------------------------------------------------------`Fruit fly' has a gene count of 13000 `Human' has a gene count of 31000 `Nematode worm' has a gene count of 18000 `Thale cress' has a gene count of 26000 `Tuberculosis ...
NETWork Therapy - Dr Robin Kroll
... mental health practioner, matching one’s therapeutic style to a specific approach is easily accessible. While a particular approach may match the needs of the therapist, does it equally meet the needs of the client? If not, can the therapeutic alliance become compromised? Therefore, one may ask: Cou ...
... mental health practioner, matching one’s therapeutic style to a specific approach is easily accessible. While a particular approach may match the needs of the therapist, does it equally meet the needs of the client? If not, can the therapeutic alliance become compromised? Therefore, one may ask: Cou ...
The importance of alternative splicing in the drug discovery process
... ▼ Mammalian genes are organized on the DNA in a typical exon–intron structure, with an average of 8.7 exons per gene [1]. Following the transcription of the DNA into pre-mRNA, the introns are cut out in a process called splicing. A huge RNA–protein complex, called a spliceosome [2,3], recognizes con ...
... ▼ Mammalian genes are organized on the DNA in a typical exon–intron structure, with an average of 8.7 exons per gene [1]. Following the transcription of the DNA into pre-mRNA, the introns are cut out in a process called splicing. A huge RNA–protein complex, called a spliceosome [2,3], recognizes con ...
5 The Genetics of Bacteria and Their Viruses
... You are given two strains of E. coli. The Hfr strain is arg+ ala+ glu+ pro+ leu+ Ts; the F– strain is arg– ala– glu– pro– leu– Tr. All the markers are nutritional except T, which determines sensitivity or resistance to phage T1. The order of entry is as given, with arg+ entering the recipient first ...
... You are given two strains of E. coli. The Hfr strain is arg+ ala+ glu+ pro+ leu+ Ts; the F– strain is arg– ala– glu– pro– leu– Tr. All the markers are nutritional except T, which determines sensitivity or resistance to phage T1. The order of entry is as given, with arg+ entering the recipient first ...
Volume 11 - Número 6 - Novembro / Dezembro de 2001
... that requires demonstration of a pressure gradient at a short distance beyond the aortic valve by echocardiography and Doppler ultrasound examination and/or left heart catheterization(14). Clinical findings include supravalvar aortic stenosis, a congenital narrowing of the ascending aorta, either lo ...
... that requires demonstration of a pressure gradient at a short distance beyond the aortic valve by echocardiography and Doppler ultrasound examination and/or left heart catheterization(14). Clinical findings include supravalvar aortic stenosis, a congenital narrowing of the ascending aorta, either lo ...
7. Rh Blood Group System - Austin Community College
... Rare persons exist whose RBCs lack the LW antigen, yet have normal Rh antigens, with or without D. These people can form alloanti-LW and this antibody reacts more strongly with D-positive than with D-negative cells. Keep in mind when a D positive individual appears to have anti-D ...
... Rare persons exist whose RBCs lack the LW antigen, yet have normal Rh antigens, with or without D. These people can form alloanti-LW and this antibody reacts more strongly with D-positive than with D-negative cells. Keep in mind when a D positive individual appears to have anti-D ...
Rectal budesonide and mesalamine formulations in active ulcerative
... treated with topical formulations (rectal suppositories, enemas, or foam) of mesalamine or steroids to reduce mucosal inflammation and alleviate symptoms. Enemas or foam formulations adequately reach up to the splenic flexure, have a minimal side-effect p rofile, and induce remission alone or in co ...
... treated with topical formulations (rectal suppositories, enemas, or foam) of mesalamine or steroids to reduce mucosal inflammation and alleviate symptoms. Enemas or foam formulations adequately reach up to the splenic flexure, have a minimal side-effect p rofile, and induce remission alone or in co ...
genetic testing for Marfan syndrome
... When someone has features of more then one disorder, a genetic test may be informative in considering differential diagnosis and may indicate a specific course of treatment. For example, people with Loeys-Dietz syndrome, a connective tissue disorder caused by mutations in the TGFBR1 or TGFBR2 genes, m ...
... When someone has features of more then one disorder, a genetic test may be informative in considering differential diagnosis and may indicate a specific course of treatment. For example, people with Loeys-Dietz syndrome, a connective tissue disorder caused by mutations in the TGFBR1 or TGFBR2 genes, m ...
Gene Section PDE11A (phosphodiesterase 11A) Atlas of Genetics and Cytogenetics
... AIMAH is a rare form of benign bilateral adrenocortical tumor. It can be associated to an overt Cushing's syndrome (CS). Nowadays, the most frequent clinical presentation is that of bilateral adrenal incidentalomas. The initial endocrine evaluation usually demonstrates subtle abnormalities of cortis ...
... AIMAH is a rare form of benign bilateral adrenocortical tumor. It can be associated to an overt Cushing's syndrome (CS). Nowadays, the most frequent clinical presentation is that of bilateral adrenal incidentalomas. The initial endocrine evaluation usually demonstrates subtle abnormalities of cortis ...
BPH
... symptoms compared to placebo Dutasteride, improved symptom scores greater after 4 years of therapy compared with 2 years (-6.4 vs -4.3 points, respectively) and flow rates were better (2.6 vs 2.3 mL/sec). Finasteride showed maintenance of the decreased risk for AUR and enlarged prostaterelated surge ...
... symptoms compared to placebo Dutasteride, improved symptom scores greater after 4 years of therapy compared with 2 years (-6.4 vs -4.3 points, respectively) and flow rates were better (2.6 vs 2.3 mL/sec). Finasteride showed maintenance of the decreased risk for AUR and enlarged prostaterelated surge ...
Background Selection in Single Genes May Explain
... may exert significant effects on sites within the same or neighboring genes. The basis for this can be understood as follows. Published data on autosomal DNA sequence polymorphisms in regions with normal recombination rates in African populations of Drosophila melanogaster yield a mean nonsynonymous ...
... may exert significant effects on sites within the same or neighboring genes. The basis for this can be understood as follows. Published data on autosomal DNA sequence polymorphisms in regions with normal recombination rates in African populations of Drosophila melanogaster yield a mean nonsynonymous ...
Reassignment of Drosophila willistoni Genome Scaffolds to
... chromosome II of D. willistoni (bw, abb, px, hk, pw, Sv, and S). Most of these mutants were obtained from a strain from Belem (Pará, Brazil), but some (e.g., bw and hk) were generated in X-rayed cultures from strains of a different origin. The eye-color mutant brown (bw) was located at one end of th ...
... chromosome II of D. willistoni (bw, abb, px, hk, pw, Sv, and S). Most of these mutants were obtained from a strain from Belem (Pará, Brazil), but some (e.g., bw and hk) were generated in X-rayed cultures from strains of a different origin. The eye-color mutant brown (bw) was located at one end of th ...
IDET – Intradiscal Electrothermal Therapy for Treatment of
... above the 42° C required for neuronal cell death (Troussier et al. 1995; Houpt et al. 1996). However, these studies have been criticized because the heating element was placed in the middle of the disc and not within the annulus. A subsequent study using the Oratec SpineCATH method reported that suf ...
... above the 42° C required for neuronal cell death (Troussier et al. 1995; Houpt et al. 1996). However, these studies have been criticized because the heating element was placed in the middle of the disc and not within the annulus. A subsequent study using the Oratec SpineCATH method reported that suf ...
Age study
... Analysis of variance (ANOVA) is a very powerful technique for identifying differentially expressed genes and can be used in either a simple or a complicated multi-factor experiment. One of the key attributes of the Partek® ANOVA is its applicability to a wide range of use cases. In this first exampl ...
... Analysis of variance (ANOVA) is a very powerful technique for identifying differentially expressed genes and can be used in either a simple or a complicated multi-factor experiment. One of the key attributes of the Partek® ANOVA is its applicability to a wide range of use cases. In this first exampl ...
Designing Clinical Trials to Evaluate Mucus
... resolution, but many of these are subjective and might be influenced by medications given concomitantly during the acute illness. Although it is theoretically attractive to begin an experimental intervention immediately following therapy for an exacerbation and using the time until the subsequent ex ...
... resolution, but many of these are subjective and might be influenced by medications given concomitantly during the acute illness. Although it is theoretically attractive to begin an experimental intervention immediately following therapy for an exacerbation and using the time until the subsequent ex ...
Multiple Myeloma Patient Management: New Agents, New Challenges
... 51% of genes shared with Foundation Heme panel, 35% with Foundation ONE Kortuem KM et al. Blood. 2015;126: Abstract 1795. Hofste op Bruinink D et al. Blood. 2015;126: Abstract 2984. Kortüm KM et al. Blood. 2016;128:1226. ...
... 51% of genes shared with Foundation Heme panel, 35% with Foundation ONE Kortuem KM et al. Blood. 2015;126: Abstract 1795. Hofste op Bruinink D et al. Blood. 2015;126: Abstract 2984. Kortüm KM et al. Blood. 2016;128:1226. ...
Protein Therapeutics..
... highly specific, there is often less potential for protein therapeutics to interfere with normal biological processes and cause adverse effects. Third, because the body naturally produces many of the proteins that are used as therapeutics, these agents are often well tolerated and are less likely to ...
... highly specific, there is often less potential for protein therapeutics to interfere with normal biological processes and cause adverse effects. Third, because the body naturally produces many of the proteins that are used as therapeutics, these agents are often well tolerated and are less likely to ...
Gene therapy
Gene therapy is the therapeutic delivery of nucleic acid polymers into a patient's cells as a drug to treat disease. Gene therapy could be a way to fix a genetic problem at its source. The polymers are either expressed as proteins, interfere with protein expression, or possibly correct genetic mutations.The most common form uses DNA that encodes a functional, therapeutic gene to replace a mutated gene. The polymer molecule is packaged within a ""vector"", which carries the molecule inside cells.Gene therapy was conceptualized in 1972, by authors who urged caution before commencing human gene therapy studies. By the late 1980s the technology had already been extensively used on animals, and the first genetic modification of a living human occurred on a trial basis in May 1989 , and the first gene therapy experiment approved by the US Food and Drug Administration (FDA) occurred on September 14, 1990, when Ashanti DeSilva was treated for ADA-SCID. By January 2014, some 2,000 clinical trials had been conducted or approved.Early clinical failures led to dismissals of gene therapy. Clinical successes since 2006 regained researchers' attention, although as of 2014, it was still largely an experimental technique. These include treatment of retinal disease Leber's congenital amaurosis, X-linked SCID, ADA-SCID, adrenoleukodystrophy, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), multiple myeloma, haemophilia and Parkinson's disease. Between 2013 and April 2014, US companies invested over $600 million in the field.The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of certain cancers. In 2011 Neovasculgen was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia.In 2012 Glybera, a treatment for a rare inherited disorder, became the first treatment to be approved for clinical use in either Europe or the United States after its endorsement by the European Commission.